SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years
ENCIRCLE mitral trial achieves primary and secondary endpoints.
Transforming Care for Severe AS Patients
EDWARDS’ SAPIEN 3 ULTRA RESILIA VALVE DEMONSTRATES CONTINUED EXCELLENT OUTCOMES FOR PATIENTS IN REAL WORLD DATA
BD announced it has completed the acquisition of Edwards Lifesciences’ Critical Care product group, which will be renamed as BD Advanced Patient Monitoring.
Edwards Lifesciences announced the results from the RHEIA Trial.
FIVE-YEAR DATA SHOW EXCELLENT OUTCOMES FOR FEMALE AND SMALL ANNULUS PATIENTS WITH EDWARDS TAVR
Agreement strengthens Edwards’ strategy to advance structural heart innovation.
LARGE, REAL-WORLD STUDIES DEMONSTRATE CONTINUED EXCELLENT OUTCOMES FOR PATIENTS RECEIVING EDWARDS SAPIEN TAVR
Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve
The company expects to receive U.S. approval late next year.
Edwards Lifesciences announced the launch of the SAPIEN 3 Ultra RESILIA valve, which incorporates Edwards’ breakthrough RESILIA tissue technology with the industry-leading SAPIEN 3 Ultra transcatheter aortic heart valve.